Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Illumina, Inc. (ILMN)
USD190.05
-0.15 (-0.08%)
US NASDAQ S&P 500
NASDAQ 100
Healthcare Medical - Diagnostics & Research
Address
5200 Illumina Way 92122
San Diego, CA, US
San Diego, CA, US
CEO
Jacob Thaysen
Website
illumina.com
IPO
2000-07-28
CIK 1110803 ISIN US4523271090
Also trades on
Deutsche Börse · ILU.DE (EUR)
London Stock Exchange · 0J8Z.L (USD)
NASDAQ Global Select · ILMN (USD)
Description
Illumina, Inc. specializes in delivering advanced genetic and genomic analysis tools, primarily through sequencing and array technologies. The company's offerings empower clients across various sectors to integrate genomic insights into both research and clinical environments, with applications spanning critical fields like life sciences, cancer diagnostics, reproductive health, agriculture, and innovative new domains. Illumina's portfolio encompasses specialized instrumentation and necessary consumables for genetic analysis, alongside comprehensive genotyping and sequencing services. They also offer instrument maintenance agreements, collaborate through development and licensing deals, and perform cancer detection tests. Its diverse clientele comprises leading genomic research facilities, universities, state-funded laboratories, medical centers, pharmaceutical and biotechnology firms, commercial molecular diagnostic providers, and businesses focused on consumer genomics. Illumina employs a two-pronged distribution strategy, selling directly to clients across North America, Europe, Latin America, and the Asia-Pacific. Additionally, it partners with life-science distributors to reach markets in Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. Established in 1998, the company maintains its corporate headquarters in San Diego, California.
News Sentiment (7d)
7 articles
Market Cap & Enterprise Value
Merger & Acquisition History
Index membership
| Index | Added | Removed | Status |
|---|---|---|---|
| S&P 500 | 2015-11-18 | — | Active |
| NASDAQ 100 | 2008-12-22 | — | Active |
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD190.05
-0.15 (-0.08%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2M
Beta
1.47
Float Shares
148.72M
Free Float %
97.9%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.44% | +0.81% | +17.85% | +24.53% | +16.83% | +8.65% | +74.71% | -29.70% | -60.67% | +7.09% | +648.87% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (50 ratings, all time)
Buy
Price Targets & DCF
Current price
190.05
Low
122.00
-35.8%
Consensus
147.38
-22.5%
Median
145.00
-23.7%
High
170.00
-10.5%
DCF (Levered)
97.55
-48.7%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
44% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 7 | -1 |
| Hold | 7 | 0 |
| Sell | 1 | 0 |
| Strong Sell | 2 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 2 |
131.00
-31.1%
|
| Last Quarter | 2 |
131.00
-31.1%
|
| Last Year | 24 |
130.42
-31.4%
|
| All Time | 66 |
198.44
+4.4%
|
Quality scores
Altman Z-Score
4.62
Safe zone
Piotroski F-Score
7 / 9
Strong
MOAT Score
6 / 10
Developing
Composite Rating
B
Overall Score
3 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
5 / 5
High
ROA Score
5 / 5
High
D/E Score
1 / 5
Low
P/E Score
2 / 5
Medium
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Diagnostics & Research: +7.9%-0.8% Q1'26: +4.8% (vs Q1'25)
-
EPS growth Medical - Diagnostics & Research: +30.8%+170.9% ★ Q1'26: +6.1% (vs Q1'25)
-
FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%+11.4% Q1'26: +23.0% (vs Q1'25)
-
EBIT margin Medical - Diagnostics & Research: +9.6%+19.9% ★ Q1'26: +21.3% (vs Q1'25)
-
ROIC Medical - Diagnostics & Research: +5.2%+18.6% ★ Q1'26: +19.9% (vs Q1'25)
-
Share dilution Medical - Diagnostics & Research: 0.0%-1.9% ★ Q1'26: -3.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×2.25× Q1'26: 2.05× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2008 actual |
Dec 2009 actual |
Dec 2013 actual |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 13 Rev. Ana. 10 EPS Ana. |
Dec 2027 13 Rev. Ana. 11 EPS Ana. |
Dec 2028 14 Rev. Ana. 6 EPS Ana. |
Dec 2029 7 Rev. Ana. 2 EPS Ana. |
Dec 2030 10 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
573.23M
est: 504.93M (+13.5%)
|
666.32M
est: 648.08M (+2.8%)
|
1.42B
est: 1.28B (+10.8%)
|
1.86B
est: 1.55B (+20.0%)
|
2.22B
est: 2.21B (+0.3%)
|
2.40B
est: 2.40B (+0.1%)
|
2.75B
est: 2.73B (+0.9%)
|
3.33B
est: 3.33B (+0.1%)
|
3.54B
est: 3.53B (+0.4%)
|
3.19B
est.
|
3.24B
est: 4.45B (-27.2%)
|
4.53B
est: 4.57B (-1.0%)
|
4.58B
est: 4.43B (+3.5%)
|
4.50B
est: 4.43B (+1.7%)
|
4.37B
est: 4.33B (+0.9%)
|
4.34B
est: 4.30B (+0.8%)
|
4.57B
4.55B – 4.59B
+6.2% YoY
|
4.82B
4.79B – 4.86B
+5.5% YoY
|
5.14B
5.14B – 5.14B
+6.6% YoY
|
5.44B
5.38B – 5.50B
+5.8% YoY
|
5.77B
5.71B – 5.83B
+6.1% YoY
|
| EBITDA |
122.62M
est: 77.73M (+57.8%)
|
169.03M
est: 137.69M (+22.8%)
|
296.93M
est: 279.33M (+6.3%)
|
603.06M
est: 481.33M (+25.3%)
|
753.00M
est: 690.73M (+9.0%)
|
735.00M
est: -265.35M (+377.0%)
|
1.24B
est: -302.14M (+509.1%)
|
1.13B
est: -368.62M (+406.6%)
|
1.36B
est: 1.16B (+17.2%)
|
912.06M
est.
|
1.09B
est: -493.01M (+321.5%)
|
1.20B
est: 948.91M (+26.0%)
|
-3.92B
est: -557.55M (-602.4%)
|
-608.00M
est: -557.55M (-9.0%)
|
-725.00M
est: -545.34M (-32.9%)
|
1.13B
est: -541.64M (+309.4%)
|
-575.16M
-577.69M – -572.64M
-6.2% YoY
|
-607.02M
-612.04M – -603.25M
-5.5% YoY
|
-646.90M
-647.27M – -646.53M
-6.6% YoY
|
-684.20M
-691.82M – -676.90M
-5.8% YoY
|
-725.96M
-734.05M – -718.21M
-6.1% YoY
|
| EBIT |
94.90M
est: 60.49M (+56.9%)
|
137.84M
est: 118.87M (+16.0%)
|
199.00M
est: 130.10M (+53.0%)
|
490.49M
est: 413.62M (+18.6%)
|
626.00M
est: 560.42M (+11.7%)
|
594.00M
est: -445.56M (+233.3%)
|
1.08B
est: -507.32M (+312.9%)
|
951.00M
est: -618.95M (+253.6%)
|
1.17B
est: 806.93M (+45.0%)
|
462.42M
est.
|
905.00M
est: -827.82M (+209.3%)
|
945.00M
est: -195.36M (+583.7%)
|
-4.31B
est: -894.63M (-381.8%)
|
-1.04B
est: -894.63M (-16.2%)
|
-1.08B
est: -875.04M (-23.3%)
|
864.00M
est: -869.10M (+199.4%)
|
-922.89M
-926.93M – -918.84M
-6.2% YoY
|
-974.00M
-982.07M – -967.95M
-5.5% YoY
|
-1.04B
-1.04B – -1.04B
-6.6% YoY
|
-1.10B
-1.11B – -1.09B
-5.8% YoY
|
-1.16B
-1.18B – -1.15B
-6.1% YoY
|
| Net Income |
50.48M
est: 25.16M (+100.6%)
|
72.28M
est: 67.80M (+6.6%)
|
125.31M
est: 120.71M (+3.8%)
|
353.35M
est: 281.85M (+25.4%)
|
461.56M
est: 421.32M (+9.5%)
|
462.65M
est: 515.68M (-10.3%)
|
726.00M
est: 584.53M (+24.2%)
|
826.00M
est: 889.67M (-7.2%)
|
1.00B
est: 847.84M (+18.2%)
|
521.95M
est.
|
656.00M
est: 884.02M (-25.8%)
|
762.00M
est: 554.35M (+37.5%)
|
-4.40B
est: -3.00B (-47.0%)
|
-1.16B
est: -3.00B (+61.3%)
|
-1.22B
est: 647.43M (-288.9%)
|
850.00M
est: 734.91M (+15.7%)
|
810.64M
797.30M – 823.98M
+10.3% YoY
|
924.48M
877.55M – 971.41M
+14.0% YoY
|
1.05B
1.02B – 1.09B
+13.9% YoY
|
1.18B
1.17B – 1.20B
+12.4% YoY
|
1.33B
1.31B – 1.34B
+12.0% YoY
|
| SGA |
148.01M
est: 155.90M (-5.1%)
|
176.34M
est: 179.69M (-1.9%)
|
381.04M
est: 334.91M (+13.8%)
|
466.28M
est: 304.33M (+53.2%)
|
516.00M
est: 501.63M (+2.9%)
|
584.00M
est: 787.55M (-25.8%)
|
674.00M
est: 896.72M (-24.8%)
|
794.00M
est: 1.09B (-27.4%)
|
835.00M
est: 703.31M (+18.7%)
|
776.85M
est.
|
941.00M
est: 1.46B (-35.7%)
|
2.09B
est: 1.59B (+31.2%)
|
1.30B
est: 1.42B (-8.6%)
|
1.61B
est: 1.42B (+13.6%)
|
1.09B
est: 1.39B (-21.3%)
|
1.08B
est: 1.38B (-21.8%)
|
1.46B
1.46B – 1.47B
+6.2% YoY
|
1.54B
1.53B – 1.56B
+5.5% YoY
|
1.65B
1.64B – 1.65B
+6.6% YoY
|
1.74B
1.72B – 1.76B
+5.8% YoY
|
1.85B
1.83B – 1.87B
+6.1% YoY
|
| EPS |
0.43
est: 0.50 (-14.0%)
|
0.59
est: 0.74 (-20.3%)
|
1.00
est: 1.43 (-30.1%)
|
2.61
est: 1.82 (+43.4%)
|
3.18
est: 3.23 (-1.7%)
|
3.15
est: 3.24 (-2.9%)
|
4.97
est: 3.68 (+35.2%)
|
5.62
est: 5.60 (+0.4%)
|
6.82
est: 6.28 (+8.6%)
|
4.28
est.
|
4.46
est: 5.56 (-19.8%)
|
5.08
est: 2.23 (+128.0%)
|
-28.05
est: -19.21 (-46.1%)
|
-7.35
est: -19.21 (+61.7%)
|
-7.69
est: 4.13 (-286.2%)
|
5.48
est: 4.73 (+15.8%)
|
5.21
5.11 – 5.28
+10.2% YoY
|
5.90
5.63 – 6.23
+13.1% YoY
|
6.75
6.51 – 6.99
+14.5% YoY
|
7.58
7.48 – 7.69
+12.3% YoY
|
8.50
8.38 – 8.62
+12.0% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-05-04 | Citigroup | Sell | Sell | Maintain |
| 2026-05-01 | Canaccord Genuity | Hold | Hold | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-08 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-07 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-06 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-05 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-04 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-01 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-30 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-29 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-28 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-27 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-24 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-23 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-22 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-21 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-20 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-17 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-16 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-15 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
1.01B
OE per share TTM
6.52
Owner's Yield
4.62%
Maintenance CapEx ratio
15.22%
Maint CapEx / Avg PPE
35.2%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
241
Total invested
747.59M
Insider transactions (90d)
0
Beneficial owners (>5%)
32
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Baillie Gifford & Co (Scottish partnership) | 20.48M | 11.00% | — | — | — | — | IA | SCOTLAND UK | 2022-01-20 | ↗ |
| 2 | The Vanguard Group - 23-1945930 | 12.20M | 7.81% | — | 256.9K | 11.57M | 631.9K | IA | Pennsylvania For | 2022-02-10 | ↗ |
| 3 | (1) BlackRock, Inc. | 11.78M | 7.50% | 10.38M | — | 11.78M | — | HC | Delaware | 2022-02-03 | ↗ |
| 4 | Sands Capital Management, LLC | 11.12M | 11.00% | 7.44M | — | 11.12M | — | IA | Reporting | 2012-02-14 | ↗ |
| 5 | Edgewood Management LLC | 8.74M | 5.60% | 8.52M | — | 8.74M | — | IA | Connecticut | 2022-02-14 | ↗ |
| 6 | Capital Research Global Investors ** | 7.99M | 5.40% | 7.99M | — | 7.99M | — | IA | Delaware | 2020-02-14 | ↗ |
| 7 | Identification #52-2069785 (formerly 13-2631108) | 7.47M | 11.00% | 4.57M | — | — | 7.47M | IA | Delaware | 2011-02-11 | ↗ |
| 8 | The Growth Fund of America, Inc. | 7.25M | 5.90% | — | — | — | — | IV | Maryland | 2013-02-13 | ↗ |
| 9 | Daniel S. Sundheim | 7.10M | 5.50% | — | 7.10M | — | 7.10M | IN | Delaware | 2014-03-10 | ↗ |
| 10 | David C. Ott | 7.10M | 5.50% | — | 7.10M | — | 7.10M | IN | Delaware | 2014-03-10 | ↗ |
| 11 | O. Andreas Halvorsen | 7.10M | 5.50% | — | 7.10M | — | 7.10M | IN | Delaware | 2014-03-10 | ↗ |
| 12 | Thomas W. Purcell, Jr. | 7.10M | 5.50% | — | 7.10M | — | 7.10M | IN | Delaware | 2014-03-10 | ↗ |
| 13 | Viking Global Investors LP | 7.10M | 5.50% | — | 7.10M | — | 7.10M | PN | Delaware | 2014-03-10 | ↗ |
| 14 | 13-3434400 | 6.92M | 11.00% | — | — | — | — | IA | Delaware | 2012-02-13 | ↗ |
| 15 | Edward C. Johnson 3d | 5.94M | 13.00% | — | — | 5.94M | — | IN | United States of America | 2006-08-10 | ↗ |
| 16 | FMR Corp. | 5.94M | 13.00% | 68.1K | — | 5.94M | — | HC | Delaware | 2006-08-10 | ↗ |
| 17 | Viking Global Performance LLC | 5.37M | 4.20% | — | 5.37M | — | 5.37M | OO | Delaware | 2014-03-10 | ↗ |
| 18 | Illumina, Inc. | 4.50M | 14.50% | 4.50M | — | 4.50M | — | CO | Delaware | 2024-08-14 | ↗ |
| 19 | Clinton Bybee | 3.62M | 11.33% | 4.6K | 3.62M | 4.6K | 3.62M | IN | U.S.A. | 2001-02-14 | ↗ |
| 20 | Keith Crandell | 3.62M | 11.33% | 4.6K | 3.62M | 4.6K | 3.62M | IN | U.S.A. | 2001-02-14 | ↗ |
| 21 | Robert Nelsen | 3.62M | 11.33% | 4.6K | 3.62M | 4.6K | 3.62M | IN | U.S.A. | 2001-02-14 | ↗ |
| 22 | Steven Lazarus | 3.62M | 11.33% | 4.6K | 3.62M | 4.6K | 3.62M | IN | U.S.A. | 2001-02-14 | ↗ |
| 23 | ARCH Venture Fund III, L.P. | 3.62M | 11.32% | — | 3.62M | — | 3.62M | PN | Delaware | 2001-02-14 | ↗ |
| 24 | ARCH Venture Partners, L.L.C. | 3.62M | 11.32% | — | 3.62M | — | 3.62M | OO | Delaware | 2001-02-14 | ↗ |
| 25 | VGE III Portfolio Ltd. | 3.41M | 2.70% | — | 3.41M | — | 3.41M | CO | Delaware | 2014-03-10 | ↗ |
| 26 | 52-0556948 | 3.39M | 6.10% | 799.4K | — | 3.39M | — | IA | MARYLAND | 2008-02-13 | ↗ |
| 27 | Federated Investors, Inc. | 3.21M | 11.00% | 3.21M | — | 3.21M | — | HC | Each Reporting | 2005-02-14 | ↗ |
| 28 | Viking Global Equities LP | 1.85M | 1.40% | — | 1.85M | — | 1.85M | PN | Delaware | 2014-03-10 | ↗ |
| 29 | Viking Long Fund GP LLC | 1.73M | 1.40% | — | 1.73M | — | 1.73M | OO | Delaware | 2014-03-10 | ↗ |
| 30 | Viking Long Fund Master Ltd. | 1.73M | 1.40% | — | 1.73M | — | 1.73M | CO | Delaware | 2014-03-10 | ↗ |
| 31 | Viking Global Equities II LP | 107.4K | 0.10% | — | 107.4K | — | 107.4K | PN | Delaware | 2014-03-10 | ↗ |
| 32 | 95-1411037 | 13.00 | 10.60% | 16.78M | — | 16.81M | — | IA | Delaware | 2024-12-05 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
241
-650 vs prev Q
New positions
26
Closed positions
642
Increased
96
Reduced
89
Put/Call ratio
0.00
Calls held
120.00
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | CAPITAL WORLD INVESTORS | 20.10M +124.3K (+0.6%) | 2.64B +739.3M (+39.0%) | 13.14% +0.494 pp | 0.36% +0.099 pp | USD124.31 +5.5% | 9 qtrs — |
| 2 | BLACKROCK, INC. | 18.32M -364.9K (-2.0%) | 2.40B +628.4M (+35.4%) | 11.98% +0.148 pp | 0.04% +0.010 pp | USD129.41 +1.4% | 6 qtrs — |
| 3 | VANGUARD GROUP INC | 14.36M -272.5K (-1.9%) | 1.88B +493.6M (+35.5%) | 9.38% +0.124 pp | 0.03% +0.007 pp | USD156.42 -16.1% | 84 qtrs — |
| 4 | STATE STREET CORP | 6.19M +190.3K (+3.2%) | 811.90M +242.1M (+42.5%) | 4.05% +0.249 pp | 0.03% +0.008 pp | USD180.13 -27.2% | 51 qtrs — |
| 5 | AQR CAPITAL MANAGEMENT LLC | 4.43M +1.0M (+30.3%) | 580.53M +264.6M (+83.8%) | 2.89% +0.742 pp | 0.30% +0.102 pp | USD101.06 +29.8% | 8 qtrs — |
| 6 | LOOMIS SAYLES & CO L P | 4.17M -115.7K (-2.7%) | 547.16M +140.0M (+34.4%) | 2.73% +0.013 pp | 0.66% +0.175 pp | USD260.72 -49.7% | 24 qtrs — |
| 7 | WCM INVESTMENT MANAGEMENT, LLC | 4.07M -110.4K (-2.6%) | 540.47M +156.3M (+40.7%) | 2.66% +0.014 pp | 1.11% +0.314 pp | USD127.81 +2.6% | 30 qtrs — |
| 8 | CORVEX MANAGEMENT LP | 3.83M +— (+0.0%) | 502.29M +138.6M (+38.1%) | 2.50% +0.079 pp | 15.35% +3.292 pp | USD96.43 +36.0% | 9 qtrs — |
| 9 | SESSA CAPITAL IM, L.P. | 3.40M -1.3M (-27.4%) | 446.48M +1.4M (+0.3%) | 2.22% -0.741 pp | 8.35% -2.188 pp | USD95.41 +37.5% | 3 qtrs — |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 2.87M +130.1K (+4.8%) | 375.26M +116.0M (+44.7%) | 1.88% +0.142 pp | 0.02% +0.007 pp | USD193.41 -32.2% | 78 qtrs — |
| 11 | INVESCO LTD. | 2.75M +1.4M (+97.0%) | 360.43M +227.9M (+172.0%) | 1.80% +0.913 pp | 0.06% +0.034 pp | USD137.02 -4.3% | 57 qtrs — |
| 12 | MORGAN STANLEY | 2.53M +1.0M (+66.0%) | 331.71M +187.0M (+129.2%) | 1.65% +0.689 pp | 0.02% +0.011 pp | USD159.76 -17.9% | 51 qtrs — |
| 13 | JANUS HENDERSON GROUP PLC | 2.07M +41.7K (+2.1%) | 271.70M +78.9M (+40.9%) | 1.35% +0.069 pp | 0.12% +0.034 pp | USD202.97 -35.4% | 67 qtrs — |
| 14 | PRIMECAP MANAGEMENT CO/CA/ | 1.99M +104.4K (+5.5%) | 260.97M +81.9M (+45.8%) | 1.30% +0.107 pp | 0.20% +0.060 pp | USD100.08 +31.1% | 73 qtrs — |
| 15 | BANK OF AMERICA CORP /DE/ | 1.84M -50.5K (-2.7%) | 241.64M +61.9M (+34.4%) | 1.20% +0.006 pp | 0.02% +0.005 pp | USD188.42 -30.4% | 52 qtrs — |
| 16 | SOUTHPOINT CAPITAL ADVISORS LP | 1.75M +250.5K (+16.7%) | 229.59M +87.1M (+61.2%) | 1.14% +0.195 pp | 5.34% +1.601 pp | USD95.83 +36.9% | 4 qtrs — |
| 17 | FMR LLC | 1.69M +123.6K (+7.9%) | 222.23M +73.1M (+49.0%) | 1.11% +0.113 pp | 0.01% +0.004 pp | USD117.85 +11.3% | 70 qtrs — |
| 18 | BAILLIE GIFFORD & CO | 1.63M -59.9K (-3.6%) | 213.37M +53.2M (+33.2%) | 1.04% -0.025 pp | 0.18% +0.059 pp | USD176.04 -25.5% | 51 qtrs — |
| 19 | BANK OF NEW YORK MELLON CORP | 1.62M -57.6K (-3.4%) | 212.93M +53.3M (+33.4%) | 1.06% -0.003 pp | 0.04% +0.007 pp | USD245.52 -46.6% | 66 qtrs — |
| 20 | UBS ASSET MANAGEMENT AMERICAS INC | 1.59M -2.3K (-0.1%) | 208.23M +57.2M (+37.9%) | 1.04% +0.031 pp | 0.04% +0.011 pp | USD155.44 -15.6% | 69 qtrs — |
| 21 | GUARDCAP ASSET MANAGEMENT LTD | 1.58M -275.2K (-14.9%) | 206.94M +31.1M (+17.7%) | 1.03% -0.142 pp | 5.53% +1.453 pp | USD226.28 -42.0% | 31 qtrs — |
| 22 | NORTHERN TRUST CORP | 1.54M -40.3K (-2.5%) | 202.43M +52.0M (+34.6%) | 1.01% +0.006 pp | 0.03% +0.007 pp | USD168.65 -22.2% | 51 qtrs — |
| 23 | ARK INVESTMENT MANAGEMENT LLC | 1.54M +72.5K (+4.9%) | 202.03M +62.6M (+44.9%) | 1.01% +0.078 pp | 1.34% +0.511 pp | USD111.86 +17.3% | 5 qtrs — |
| 24 | UBS GROUP AG | 1.52M +27.3K (+1.8%) | 199.67M +57.7M (+40.6%) | 1.00% +0.049 pp | 0.03% +0.010 pp | USD111.93 +17.2% | 45 qtrs — |
| 25 | SENVEST MANAGEMENT, LLC | 1.40M -9.5K (-0.7%) | 183.87M +49.8M (+37.2%) | 0.92% +0.023 pp | 5.70% +1.396 pp | USD129.38 +1.4% | 12 qtrs — |
| 26 | SUMITOMO MITSUI TRUST HOLDINGS, INC. | 1.25M -35.2K (-2.7%) | 164.55M +42.1M (+34.3%) | 0.80% -0.012 pp | 0.10% +0.026 pp | USD149.76 -12.4% | 59 qtrs — |
| 27 | AMERIPRISE FINANCIAL INC | 1.21M +748.4K (+162.4%) | 158.58M +114.8M (+262.5%) | 0.79% +0.499 pp | 0.04% +0.026 pp | USD131.06 +0.1% | 55 qtrs — |
| 28 | PGGM INVESTMENTS | 1.15M +— (+0.0%) | 150.76M +41.6M (+38.1%) | 0.75% +0.024 pp | 2.39% +0.621 pp | USD110.57 +18.6% | 14 qtrs — |
| 29 | RENAISSANCE TECHNOLOGIES LLC | 1.13M -70.3K (-5.8%) | 148.82M +34.4M (+30.0%) | 0.74% -0.021 pp | 0.23% +0.080 pp | USD115.12 +13.9% | 9 qtrs — |
| 30 | LEGAL & GENERAL GROUP PLC | 1.13M -116.0K (-9.3%) | 148.04M +29.8M (+25.2%) | 0.74% -0.050 pp | 0.03% +0.006 pp | USD190.05 -31.0% | 68 qtrs — |
| 31 | EDMOND DE ROTHSCHILD HOLDING S.A. | 1.02M -153.3K (-13.1%) | 133.90M +22.4M (+20.1%) | 0.67% -0.076 pp | 1.90% +0.179 pp | USD105.28 +24.6% | 43 qtrs — |
| 32 | NORDEA INVESTMENT MANAGEMENT AB | 944.5K +911.8K (+2,792.2%) | 124.15M +121.1M (+4,005.9%) | 0.61% +0.585 pp | 0.11% +0.104 pp | USD133.19 -1.5% | 51 qtrs — |
| 33 | NIKKO ASSET MANAGEMENT AMERICAS, INC. | 886.9K -30.4K (-3.3%) | 116.24M +29.2M (+33.6%) | 0.58% -0.001 pp | 1.34% +0.500 pp | USD112.74 +16.3% | 5 qtrs — |
| 34 | FIRST TRUST ADVISORS LP | 870.6K +405.7K (+87.2%) | 114.19M +70.0M (+158.6%) | 0.57% +0.275 pp | 0.08% +0.050 pp | USD138.54 -5.3% | 51 qtrs — |
| 35 | LETKO, BROSSEAU & ASSOCIATES INC | 859.0K +4.7K (+0.5%) | 112.67M +31.5M (+38.9%) | 0.56% +0.021 pp | 1.84% +0.451 pp | USD120.58 +8.8% | 6 qtrs — |
| 36 | CITADEL ADVISORS LLC | 838.3K -637.3K (-43.2%) | 109.95M -30.2M (-21.5%) | 0.55% -0.386 pp | 0.02% -0.005 pp | USD102.08 +28.5% | 38 qtrs — |
| 37 | FEDERATED HERMES, INC. | 836.4K +34.8K (+4.3%) | 109.70M +33.6M (+44.1%) | 0.55% +0.039 pp | 0.18% +0.049 pp | USD101.39 +29.4% | 53 qtrs — |
| 38 | SWEDBANK AB | 826.2K +695.0 (+0.1%) | 108.36M +30.0M (+38.2%) | 0.54% +0.018 pp | 0.10% +0.025 pp | USD98.18 +33.6% | 20 qtrs — |
| 39 | JPMORGAN CHASE & CO | 775.1K -57.6K (-6.9%) | 101.67M +22.6M (+28.6%) | 0.51% -0.020 pp | 0.01% +0.002 pp | USD150.61 -12.9% | 51 qtrs — |
| 40 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 653.2K +97.1K (+17.5%) | 85.67M +32.9M (+62.2%) | 0.43% +0.075 pp | 0.01% +0.004 pp | USD120.40 +8.9% | 51 qtrs — |
| 41 | ROYAL BANK OF CANADA | 653.0K -261.4K (-28.6%) | 85.64M -1.2M (-1.4%) | 0.43% -0.152 pp | 0.01% 0.000 pp | USD137.13 -4.4% | 51 qtrs — |
| 42 | POINTSTATE CAPITAL LP | 646.9K -1.0M (-60.7%) | 84.85M -71.6M (-45.8%) | 0.42% -0.620 pp | 1.25% -1.086 pp | USD101.21 +29.6% | 5 qtrs — |
| 43 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 615.5K +16.0K (+2.7%) | 80.73M +23.8M (+41.8%) | 0.40% +0.023 pp | 0.01% +0.004 pp | USD195.77 -33.0% | 100 qtrs — |
| 44 | RHUMBLINE ADVISERS | 602.4K -16.3K (-2.6%) | 79.01M +20.3M (+34.5%) | 0.39% +0.002 pp | 0.06% +0.017 pp | USD133.86 -2.0% | 51 qtrs — |
| 45 | THRIVENT FINANCIAL FOR LUTHERANS | 600.7K -89.9K (-13.0%) | 78.79M +13.2M (+20.1%) | 0.39% -0.052 pp | 0.14% +0.011 pp | USD98.50 +33.2% | 54 qtrs — |
| 46 | CASDIN CAPITAL, LLC | 600.0K +75.0K (+14.3%) | 78.70M +28.8M (+57.8%) | 0.39% +0.060 pp | 4.89% +0.731 pp | USD124.29 +5.5% | 14 qtrs — |
| 47 | BROWN ADVISORY INC | 589.2K -28.2K (-4.6%) | 77.28M +18.6M (+31.8%) | 0.39% -0.006 pp | 0.11% +0.032 pp | USD115.16 +13.9% | 56 qtrs — |
| 48 | PATIENT CAPITAL MANAGEMENT, LLC | 575.8K -5.6K (-1.0%) | 75.52M +20.3M (+36.8%) | 0.38% +0.008 pp | 2.91% +0.705 pp | USD113.54 +15.5% | 9 qtrs — |
| 49 | DIMENSIONAL FUND ADVISORS LP | 564.2K +6.7K (+1.2%) | 74.01M +21.1M (+39.8%) | 0.37% +0.016 pp | 0.02% +0.004 pp | USD139.14 -5.7% | 51 qtrs — |
| 50 | MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 560.6K +560.6K (+100.0%) | 73.53M +73.5M (+100.0%) | 0.36% +0.359 pp | 0.02% +0.024 pp | USD131.16 +0.0% | 1 qtrs NEW |
| 51 | NORGES BANK | 540.1K +540.1K (+100.0%) | 70.84M +70.8M (+100.0%) | 0.35% +0.353 pp | 0.01% +0.008 pp | USD131.16 +0.0% | 1 qtrs NEW |
| 52 | QUANTINNO CAPITAL MANAGEMENT LP | 520.9K +110.8K (+27.0%) | 68.33M +29.4M (+75.4%) | 0.34% +0.081 pp | 0.14% +0.031 pp | USD103.33 +26.9% | 9 qtrs — |
| 53 | ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 496.8K +269.2K (+118.2%) | 65.16M +43.5M (+201.4%) | 0.32% +0.181 pp | 0.04% +0.025 pp | USD115.73 +13.3% | 5 qtrs — |
| 54 | CHEVY CHASE TRUST HOLDINGS, LLC | 467.6K +8.1K (+1.8%) | 61.33M +17.7M (+40.5%) | 0.31% +0.015 pp | 0.17% +0.046 pp | USD184.70 -29.0% | 47 qtrs — |
| 55 | PACER ADVISORS, INC. | 463.6K -185.7K (-28.6%) | 60.81M -853.0K (-1.4%) | 0.30% -0.114 pp | 0.16% +0.000 pp | USD94.97 +38.1% | 41 qtrs — |
| 56 | STIFEL FINANCIAL CORP | 457.1K -39.9K (-8.0%) | 59.95M +12.8M (+27.0%) | 0.30% -0.016 pp | 0.05% +0.011 pp | USD122.02 +7.5% | 48 qtrs — |
| 57 | M&G PLC | 428.0K -11.7K (-2.7%) | 56.06M +14.3M (+34.2%) | 0.28% +0.002 pp | 0.29% +0.066 pp | USD99.91 +31.3% | 8 qtrs — |
| 58 | SWISS NATIONAL BANK | 421.1K -35.2K (-7.7%) | 55.23M +11.9M (+27.5%) | 0.28% -0.014 pp | 0.03% +0.008 pp | USD209.51 -37.4% | 51 qtrs — |
| 59 | KEYBANK NATIONAL ASSOCIATION/OH | 418.0K +18.4K (+4.6%) | 54.82M +16.9M (+44.5%) | 0.27% +0.015 pp | 0.20% +0.063 pp | USD127.48 +2.9% | 41 qtrs — |
| 60 | RAYMOND JAMES FINANCIAL INC | 411.5K +37.6K (+10.1%) | 53.97M +18.5M (+52.0%) | 0.27% +0.032 pp | 0.02% +0.005 pp | USD132.92 -1.3% | 5 qtrs — |
| 61 | GOLDMAN SACHS GROUP INC | 410.0K -91.5K (-18.3%) | 53.77M +6.1M (+12.9%) | 0.26% -0.055 pp | 0.01% +0.001 pp | USD129.12 +1.6% | 73 qtrs — |
| 62 | NUVEEN, LLC | 407.9K +144.9K (+55.1%) | 53.50M +28.5M (+114.2%) | 0.27% +0.100 pp | 0.01% +0.007 pp | USD99.08 +32.4% | 4 qtrs — |
| 63 | JACOBS LEVY EQUITY MANAGEMENT, INC | 405.2K -697.3K (-63.2%) | 53.15M -51.6M (-49.2%) | 0.26% -0.433 pp | 0.21% -0.211 pp | USD79.80 +64.4% | 10 qtrs — |
| 64 | IEQ CAPITAL, LLC | 401.7K +85.7K (+27.1%) | 52.69M +22.7M (+75.6%) | 0.26% +0.063 pp | 0.16% +0.067 pp | USD104.99 +24.9% | 22 qtrs — |
| 65 | SPYGLASS CAPITAL MANAGEMENT LLC | 401.5K -20.6K (-4.9%) | 52.67M +12.6M (+31.4%) | 0.26% -0.005 pp | 2.64% +0.497 pp | USD124.34 +5.5% | 5 qtrs — |
| 66 | TRIPLE FROND PARTNERS LLC | 374.2K -16.4K (-4.2%) | 49.08M +12.0M (+32.3%) | 0.24% -0.003 pp | 5.10% +1.059 pp | USD94.97 +38.1% | 2 qtrs — |
| 67 | DEUTSCHE BANK AG\ | 369.0K +74.7K (+25.4%) | 48.39M +20.4M (+73.2%) | 0.24% +0.055 pp | 0.02% +0.006 pp | USD205.46 -36.2% | 50 qtrs — |
| 68 | VIRGINIA RETIREMENT SYSTEMS ET AL | 348.0K +74.9K (+27.4%) | 45.65M +19.7M (+76.0%) | 0.22% +0.050 pp | 0.27% +0.103 pp | USD102.76 +27.6% | 2 qtrs — |
| 69 | STEPHENS INVESTMENT MANAGEMENT GROUP LLC | 342.6K +47.1K (+15.9%) | 44.93M +16.9M (+60.1%) | 0.22% +0.033 pp | 0.59% +0.221 pp | USD136.31 -3.8% | 70 qtrs — |
| 70 | CAISSE DE DEPOT ET PLACEMENT DU QUEBEC | 338.3K +185.8K (+121.9%) | 44.37M +29.9M (+206.4%) | 0.22% +0.125 pp | 0.08% +0.049 pp | USD114.85 +14.2% | 2 qtrs — |
| 71 | DOUGLAS LANE & ASSOCIATES, LLC | 333.6K +26.0K (+8.5%) | 43.76M +14.5M (+49.8%) | 0.21% +0.019 pp | 0.60% +0.191 pp | USD147.35 -11.0% | 40 qtrs — |
| 72 | — | 332.0K +332.0K (+100.0%) | 43.55M +43.5M (+100.0%) | 0.22% +0.217 pp | 5.08% +5.079 pp | USD131.16 +0.0% | 1 qtrs NEW |
| 73 | CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM | 330.7K +3.0K (+0.9%) | 43.37M +12.2M (+39.4%) | 0.22% +0.009 pp | 0.02% +0.006 pp | USD145.64 -9.9% | 54 qtrs — |
| 74 | FRANKLIN RESOURCES INC | 328.9K +267.4K (+435.5%) | 43.13M +37.3M (+639.5%) | 0.21% +0.176 pp | 0.01% +0.009 pp | USD139.11 -5.7% | 51 qtrs — |
| 75 | PRINCIPAL FINANCIAL GROUP INC | 328.6K -12.9K (-3.8%) | 43.10M +10.7M (+32.9%) | 0.21% -0.006 pp | 0.02% +0.006 pp | USD157.43 -16.7% | 71 qtrs — |
| 76 | DIAMOND HILL CAPITAL MANAGEMENT INC | 327.3K -15.6K (-4.6%) | 42.93M +10.4M (+31.8%) | 0.21% -0.003 pp | 0.22% +0.065 pp | USD81.49 +61.0% | 4 qtrs — |
| 77 | PEAK6 LLC | 320.3K +35.8K (+12.6%) | 42.01M +15.0M (+55.5%) | 0.21% +0.025 pp | 0.08% +0.038 pp | USD100.64 +30.3% | 5 qtrs — |
| 78 | GOTHAM ASSET MANAGEMENT, LLC | 315.0K +22.3K (+7.6%) | 41.32M +13.5M (+48.6%) | 0.21% +0.021 pp | 0.15% +0.030 pp | USD99.42 +31.9% | 23 qtrs — |
| 79 | ENVESTNET ASSET MANAGEMENT INC | 312.0K -3.3K (-1.0%) | 40.92M +11.0M (+36.7%) | 0.20% +0.004 pp | 0.01% +0.004 pp | USD156.94 -16.4% | 51 qtrs — |
| 80 | PICTET ASSET MANAGEMENT HOLDING SA | 302.4K -21.1K (-6.5%) | 40.42M +10.5M (+35.1%) | 0.19% -0.011 pp | 0.04% +0.010 pp | USD118.71 +10.5% | 10 qtrs — |
| 81 | AMUNDI | 307.7K +12.4K (+4.2%) | 40.35M +10.5M (+35.3%) | 0.20% +0.014 pp | 0.01% +0.001 pp | USD159.73 -17.9% | 19 qtrs — |
| 82 | CIBC PRIVATE WEALTH GROUP, LLC | 302.8K +3.4K (+1.1%) | 39.72M +11.3M (+39.7%) | 0.20% +0.008 pp | 0.07% +0.019 pp | USD104.35 +25.7% | 33 qtrs — |
| 83 | NATIXIS ADVISORS, L.P. | 301.0K -16.8K (-5.3%) | 39.48M +9.3M (+30.8%) | 0.20% -0.004 pp | 0.06% +0.012 pp | USD253.48 -48.3% | 33 qtrs — |
| 84 | ILEX CAPITAL PARTNERS (UK) LLP | 296.9K -385.5K (-56.5%) | 38.94M -25.9M (-39.9%) | 0.19% -0.238 pp | 1.10% -0.970 pp | USD94.64 +38.6% | 4 qtrs — |
| 85 | OVERSEA-CHINESE BANKING CORP LTD | 272.9K -28.0K (-9.3%) | 35.80M +7.2M (+25.3%) | 0.17% -0.016 pp | 0.94% +0.240 pp | USD111.95 +17.2% | 13 qtrs — |
| 86 | JUPITER ASSET MANAGEMENT LTD | 271.4K +95.6K (+54.4%) | 35.59M +18.9M (+113.2%) | 0.18% +0.066 pp | 0.28% +0.142 pp | USD107.72 +21.8% | 2 qtrs — |
| 87 | BRAIDWELL LP | 269.7K +269.7K (+100.0%) | 35.37M +35.4M (+100.0%) | 0.18% +0.176 pp | 1.13% +1.131 pp | USD131.16 +0.0% | 1 qtrs NEW |
| 88 | ASR VERMOGENSBEHEER N.V. | 268.5K +4.2K (+1.6%) | 35.21M +10.1M (+40.3%) | 0.17% +0.005 pp | 0.41% +0.105 pp | USD83.58 +56.9% | 4 qtrs — |
| 89 | CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. | 255.4K +121.0K (+90.1%) | 33.50M +20.7M (+162.5%) | 0.17% +0.082 pp | 0.09% +0.048 pp | USD109.60 +19.7% | 42 qtrs — |
| 90 | CITIGROUP INC | 247.2K +80.1K (+47.9%) | 32.42M +16.5M (+104.3%) | 0.16% +0.056 pp | 0.01% +0.007 pp | USD147.32 -11.0% | 88 qtrs — |
| 91 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 241.4K -18.1K (-7.0%) | 31.66M +7.0M (+28.5%) | 0.16% -0.007 pp | 0.03% +0.006 pp | USD143.07 -8.3% | 52 qtrs — |
| 92 | ALLIANCEBERNSTEIN L.P. | 236.8K +1.5K (+0.6%) | 31.06M +8.7M (+39.0%) | 0.15% +0.006 pp | 0.01% +0.003 pp | USD206.17 -36.4% | 61 qtrs — |
| 93 | GREAT WEST LIFE ASSURANCE CO /CAN/ | 233.6K -34.9K (-13.0%) | 30.63M +6.0M (+24.2%) | 0.15% -0.017 pp | 0.05% +0.018 pp | USD159.15 -17.6% | 55 qtrs — |
| 94 | BAIRD FINANCIAL GROUP, INC. | 232.7K -51.1K (-18.0%) | 30.52M +3.6M (+13.3%) | 0.15% -0.028 pp | 0.05% +0.004 pp | USD88.36 +48.4% | 43 qtrs — |
| 95 | EAGLE HEALTH INVESTMENTS LP | 231.2K -91.1K (-28.3%) | 30.32M -286.1K (-0.9%) | 0.15% -0.053 pp | 6.66% -1.372 pp | USD153.13 -14.3% | 15 qtrs — |
| 96 | MITSUBISHI UFJ TRUST & BANKING CORP | 229.4K +36.2K (+18.7%) | 30.09M +11.7M (+64.0%) | 0.15% +0.025 pp | 0.07% +0.031 pp | USD122.21 +7.3% | 67 qtrs — |
| 97 | BAMCO INC /NY/ | 219.6K +11.5K (+5.5%) | 28.80M +9.0M (+45.7%) | 0.14% +0.012 pp | 0.08% +0.026 pp | USD126.54 +3.7% | 63 qtrs — |
| 98 | SPEARS ABACUS ADVISORS LLC | 218.2K -21.1K (-8.8%) | 28.61M +5.9M (+25.9%) | 0.14% -0.009 pp | 0.54% +0.107 pp | USD106.60 +23.0% | 8 qtrs — |
Ownership breakdown by holder
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
1.24
Neutral
Ratio by volume
3.00
Bullish
Buys
26
Sells
21
Shares acquired
171.5K
Shares disposed
45.0K
Cash buys
1.00
Cash sales
2.00
Net activity
+126,426
Insider buys vs sells (history)
From
To
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
96.3K
Shares Outstanding
151.91M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Jacob Thaysen Chief Executive Officer | 1.00M | — | 8.76M | — | 1.16M | 100.8K | 11.02M | 79.53% | ↗ |
| 2 | 2025 | Everett Cunningham Former Chief Commercial Officer | 650.0K | 500.0K | 2.87M | — | — | 65.9K | 4.09M | 70.25% | ↗ |
| 3 | 2025 | Ankur Dhingra Chief Financial Officer | 650.0K | — | 3.09M | — | 325.3K | 10.7K | 4.08M | 75.82% | ↗ |
| 4 | 2025 | Steve Barnard Chief Technology Officer | 600.0K | — | 2.56M | — | 300.3K | 17.7K | 3.48M | 73.62% | ↗ |
| 5 | 2025 | Kevin Pegels Chief of Global Operations | 575.0K | — | 2.30M | — | 287.8K | 20.2K | 3.18M | 72.23% | ↗ |
| 6 | 2024 | Jacob Thaysen Chief Executive Officer | 1.00M | — | 12.31M | — | 1.16M | 333.9K | 14.80M | 83.14% | ↗ |
| 7 | 2024 | Everett Cunningham Former Chief Commercial Officer | 350.0K | 500.0K | 8.72M | — | 219.1K | 286.2K | 10.07M | 86.55% | ↗ |
| 8 | 2024 | Everett Cunningham Chief Commercial Officer | 350.0K | 500.0K | 8.72M | — | 219.1K | 286.2K | 10.07M | 86.55% | ↗ |
| 9 | 2024 | Ankur Dhingra Chief Financial Officer | 450.0K | 500.0K | 4.01M | — | 279.6K | 615.5K | 5.86M | 68.49% | ↗ |
| 10 | 2024 | Charles Dadswell Former General Counsel & Secretary | 614.6K | — | 3.51M | — | 371.8K | 16.0K | 4.52M | 77.81% | ↗ |
| 11 | 2024 | Joydeep Goswami Former Chief Financial Officer, Chief Strategy and Corporate Development Officer | 318.9K | 360.0K | 2.93M | — | — | 636.0K | 4.24M | 69.01% | ↗ |
| 12 | 2024 | Steve Barnard Chief Technology Officer | 593.3K | — | 3.05M | — | 359.0K | 22.7K | 4.02M | 75.75% | ↗ |
| 13 | 2024 | Kevin Pegels Chief of Global Operations | 561.5K | — | 2.93M | — | 340.1K | 19.4K | 3.85M | 76.08% | ↗ |
| 14 | 2023 | Francis deSouza Former Chief Executive Officer | 518.4K | — | 13.97M | — | — | 6.8K | 14.49M | 96.38% | ↗ |
| 15 | 2023 | Susan Tousi Former Chief Commercial Officer | 619.2K | — | 4.47M | — | 187.5K | 57.3K | 5.33M | 83.80% | ↗ |
| 16 | 2023 | Joydeep Goswami Former Chief Financial Officer, Chief Strategy and Corporate Development Officer | 594.2K | 50.0K | 4.47M | — | 180.0K | 19.3K | 5.31M | 84.13% | ↗ |
| 17 | 2023 | Joydeep Goswami Chief Financial Officer, Chief Strategy and Corporate Development Officer | 594.2K | 50.0K | 4.47M | — | 180.0K | 19.3K | 5.31M | 84.13% | ↗ |
| 18 | 2023 | Alex Aravanis Former Chief Technology Officer, Head of Research and Product Development | 402.9K | — | 4.47M | — | 187.5K | 8.3K | 5.07M | 88.19% | ↗ |
| 19 | 2023 | Jacob Thaysen Chief Executive Officer | 250.0K | 500.0K | 3.89M | — | — | 46.6K | 4.69M | 83.02% | ↗ |
| 20 | 2023 | Phil Febbo Former Chief Medical Officer | 375.5K | — | 3.35M | — | 180.0K | 617.7K | 4.53M | 74.08% | ↗ |
| 21 | 2023 | Charles Dadswell Former General Counsel & Secretary | 594.2K | 200.0K | 3.07M | — | 250.0K | 22.0K | 4.14M | 74.25% | ↗ |
| 22 | 2023 | Charles Dadswell General Counsel & Secretary | 594.2K | 200.0K | 3.07M | — | 214.2K | 22.0K | 4.10M | 74.89% | ↗ |
| 23 | 2023 | Kathryne Reeves Former Chief Marketing Officer | 544.2K | — | 3.07M | — | 165.0K | 15.6K | 3.80M | 80.92% | ↗ |
| 24 | 2023 | Carissa Rollins Chief Information Officer | 519.2K | — | 2.24M | — | 157.5K | 16.8K | 2.93M | 76.32% | ↗ |
| 25 | 2022 | Francis deSouza Former Chief Executive Officer | 1.10M | — | 12.50M | 12.50M | 594.0K | 57.9K | 26.75M | 93.45% | ↗ |
| 26 | 2022 | Susan Tousi Former Chief Commercial Officer | 588.5K | — | 4.00M | 4.00M | 144.0K | 57.7K | 8.79M | 91.01% | ↗ |
| 27 | 2022 | Alex Aravanis Former Chief Technology Officer, Head of Research and Product Development | 588.5K | — | 4.00M | 4.00M | 144.0K | 14.2K | 8.75M | 91.46% | ↗ |
| 28 | 2022 | Phil Febbo Former Chief Medical Officer | 563.5K | — | 4.00M | — | 138.0K | 20.2K | 4.72M | 84.72% | ↗ |
| 29 | 2022 | Joydeep Goswami Chief Financial Officer, Chief Strategy and Corporate Development Officer | 519.2K | 125.0K | 2.75M | — | 126.0K | 17.1K | 3.54M | 77.74% | ↗ |
| 30 | 2022 | Joydeep Goswami Former Chief Financial Officer, Chief Strategy and Corporate Development Officer | 519.2K | 125.0K | 2.75M | — | 126.0K | 17.1K | 3.54M | 77.74% | ↗ |
| 31 | 2022 | Charles Dadswell Former General Counsel & Secretary | 569.2K | — | 2.75M | — | 138.0K | 20.3K | 3.48M | 79.08% | ↗ |
| 32 | 2022 | Charles Dadswell General Counsel & Secretary | 569.2K | — | 2.75M | — | 138.0K | 20.3K | 3.48M | 79.08% | ↗ |
| 33 | 2021 | Robert Ragusa Former Chief Operations Officer | 569.8K | 3.25M | 18.80M | — | 247.5K | 17.7K | 22.89M | 82.15% | ↗ |
| 34 | 2021 | Francis deSouza Chief Executive Officer; Director | 1.09M | — | 11.00M | — | 2.23M | 17.0K | 14.33M | 76.75% | ↗ |
| 35 | 2021 | Francis deSouza Former Chief Executive Officer | 1.09M | — | 11.00M | — | 2.23M | 17.0K | 14.33M | 76.75% | ↗ |
| 36 | 2021 | Alex Aravanis Former Chief Technology Officer, Head of Research and Product Development | 538.5K | — | 4.00M | — | 495.0K | 17.6K | 5.05M | 79.19% | ↗ |
| 37 | 2021 | Alex Aravanis Chief Technology Officer, Head of Research and Product Development | 538.5K | — | 4.00M | — | 495.0K | 17.6K | 5.05M | 79.19% | ↗ |
| 38 | 2021 | Susan Tousi Former Chief Commercial Officer | 532.7K | — | 4.00M | — | 495.0K | 13.4K | 5.04M | 79.35% | ↗ |
| 39 | 2021 | Susan Tousi Chief Commercial Officer | 532.7K | — | 4.00M | — | 495.0K | 13.4K | 5.04M | 79.35% | ↗ |
| 40 | 2021 | Charles Dadswell General Counsel & Secretary | 544.2K | — | 2.50M | — | 495.0K | 21.5K | 3.56M | 70.22% | ↗ |
| 41 | 2021 | Charles Dadswell General Counsel | 544.2K | — | 2.50M | — | 495.0K | 21.5K | 3.56M | 70.22% | ↗ |
| 42 | 2021 | Sam Samad Chief Financial Officer | 544.2K | — | 2.50M | — | 495.0K | 19.8K | 3.56M | 70.25% | ↗ |
| 43 | 2020 | Francis deSouza Chief Executive Officer; Director | 1.09M | — | 10.00M | — | 630.0K | 13.1K | 11.73M | 85.23% | ↗ |
| 44 | 2020 | Francis A. deSouza Chief Executive Officer; Director | 1.09M | — | 10.00M | — | 630.0K | 13.1K | 11.73M | 85.23% | ↗ |
| 45 | 2020 | Alex Aravanis Chief Technology Officer | 288.5K | 100.0K | 5.00M | — | 23.1K | 4.9K | 5.42M | 92.31% | ↗ |
| 46 | 2020 | Alex Aravanis Chief Technology Officer, Head of Research and Product Development | 288.5K | 100.0K | 5.00M | — | 23.1K | 4.9K | 5.42M | 92.31% | ↗ |
| 47 | 2020 | Mark Van Oene Former Chief Commercial Officer | 575.2K | — | 2.50M | — | 157.5K | 12.8K | 3.25M | 77.03% | ↗ |
| 48 | 2020 | Susan Tousi Chief Commercial Officer | 493.3K | — | 2.50M | — | 142.5K | 19.5K | 3.16M | 79.23% | ↗ |
| 49 | 2020 | Susan Tousi Chief Product Officer | 493.3K | — | 2.50M | — | 142.5K | 19.5K | 3.16M | 79.23% | ↗ |
| 50 | 2020 | Sam Samad Chief Financial Officer | 545.2K | — | 1.75M | — | 157.5K | 13.3K | 2.47M | 70.97% | ↗ |
| 51 | 2020 | Sam A. Samad Chief Financial Officer | 545.2K | — | 1.75M | — | 157.5K | 13.3K | 2.47M | 70.97% | ↗ |
| 52 | 2019 | Joydeep Goswami Senior Vice President, Corporate Development and Strategic Planning | 109.7K | 250.0K | 1.60M | — | 24.6K | 92.00 | 1.98M | 80.63% | ↗ |
| 53 | 2019 | Francis deSouza Chief Executive Officer; Director | 1.03M | — | — | — | 403.2K | 90.3K | 1.52M | 0.00% | ↗ |
| 54 | 2019 | Francis A. deSouza President and CEO; Director | 1.03M | — | — | — | 403.2K | 90.3K | 1.52M | 0.00% | ↗ |
| 55 | 2019 | Francis A. deSouza Chief Executive Officer; Director | 1.03M | — | — | — | 403.2K | 90.3K | 1.52M | 0.00% | ↗ |
| 56 | 2019 | Aimee Hoyt Senior Vice President & Chief People Officer | 476.0K | — | — | — | 91.2K | 296.9K | 864.1K | 0.00% | ↗ |
| 57 | 2019 | Omead Ostadan Chief Product and Marketing Officer | 611.5K | — | — | — | 120.0K | 12.6K | 744.1K | 0.00% | ↗ |
| 58 | 2019 | Sam A. Samad Chief Financial Officer | 507.5K | — | — | — | 100.8K | 18.4K | 626.7K | 0.00% | ↗ |
| 59 | 2019 | Sam Samad Chief Financial Officer | 507.5K | — | — | — | 100.8K | 18.4K | 626.7K | 0.00% | ↗ |
| 60 | 2019 | Sam A. Samad Senior Vice President and Chief Financial Officer | 507.5K | — | — | — | 100.8K | 18.4K | 626.7K | 0.00% | ↗ |
| 61 | 2018 | Francis A. deSouza President and CEO; Director | 937.7K | — | 8.50M | — | 1.46M | 174.8K | 11.07M | 76.80% | ↗ |
| 62 | 2018 | Francis A. deSouza Chief Executive Officer; Director | 937.7K | — | 8.50M | — | 1.46M | 174.8K | 11.07M | 76.80% | ↗ |
| 63 | 2018 | Omead Ostadan Chief Product and Marketing Officer | 569.9K | — | 3.50M | — | 560.6K | 85.9K | 4.72M | 74.21% | ↗ |
| 64 | 2018 | Omead Ostadan Senior Vice President, Marketing, Products & Strategic Planning | 569.9K | — | 3.50M | — | 560.6K | 85.9K | 4.72M | 74.21% | ↗ |
| 65 | 2018 | Aimee Hoyt Senior Vice President & Chief People Officer | 435.3K | — | 2.90M | — | 371.9K | 149.2K | 3.86M | 75.20% | ↗ |
| 66 | 2018 | Garret Hampton, Ph.D. Senior Vice President, Clinical Genomics | 504.8K | — | 2.50M | — | 511.9K | 71.7K | 3.59M | 69.67% | ↗ |
| 67 | 2018 | Sam A. Samad Chief Financial Officer | 457.3K | — | 2.00M | — | 379.5K | 60.0K | 2.90M | 69.05% | ↗ |
| 68 | 2018 | Sam A. Samad Senior Vice President and Chief Financial Officer | 457.3K | — | 2.00M | — | 379.5K | 60.0K | 2.90M | 69.05% | ↗ |
| 69 | 2017 | Francis A. deSouza President and CEO; Director | 849.0K | — | 7.00M | — | 901.0K | 57.4K | 8.81M | 79.48% | ↗ |
| 70 | 2017 | Garret Hampton Executive Vice President, Clinical Genomics | 424.0K | 200.0K | 4.50M | — | 303.8K | 494.3K | 5.92M | 75.99% | ↗ |
| 71 | 2017 | Garret Hampton, Ph.D. Senior Vice President, Clinical Genomics | 424.0K | 200.0K | 4.50M | — | 303.8K | 494.3K | 5.92M | 75.99% | ↗ |
| 72 | 2017 | Marc A. Stapley Executive Vice President, Strategy and Corporate Development | 556.1K | — | 2.50M | — | 383.2K | 17.7K | 3.46M | 72.32% | ↗ |
| 73 | 2017 | Omead Ostadan Senior Vice President, Marketing, Products & Strategic Planning | 552.5K | — | 2.50M | — | 383.2K | 17.4K | 3.45M | 72.40% | ↗ |
| 74 | 2017 | Omead Ostadan Chief Product and Marketing Officer | 552.5K | — | 2.50M | — | 383.2K | 17.4K | 3.45M | 72.40% | ↗ |
| 75 | 2017 | Omead Ostadan Executive Vice President, Products and Operations | 552.5K | — | 2.50M | — | 383.2K | 17.4K | 3.45M | 72.40% | ↗ |
| 76 | 2017 | Sam A. Samad Senior Vice President and Chief Financial Officer | 425.8K | — | 2.50M | — | 259.7K | 104.6K | 3.29M | 75.99% | ↗ |
| 77 | 2017 | Mark Van Oene Senior Vice President and Chief Commercial Officer | 518.2K | — | 2.40M | — | 162.7K | 25.7K | 3.11M | 77.26% | ↗ |
| 78 | 2016 | Francis A. deSouza President and CEO; Director | 799.6K | — | 7.50M | — | — | 109.1K | 8.41M | 89.19% | ↗ |
| 79 | 2016 | Mostafa Ronaghi Senior Vice President, Clinical Genomics | 438.6K | — | 3.00M | — | — | 12.6K | 3.45M | 86.93% | ↗ |
| 80 | 2016 | Jay T. Flatley Executive Chairman | 771.2K | — | 2.00M | — | — | 220.7K | 2.99M | 66.85% | ↗ |
| 81 | 2016 | Marc A. Stapley Executive Vice President, Strategy and Corporate Development | 540.0K | — | 2.30M | — | — | 16.5K | 2.86M | 80.52% | ↗ |
| 82 | 2016 | Marc A. Stapley Executive Vice President, Chief Administrative Officer | 540.0K | — | 2.30M | — | — | 16.5K | 2.86M | 80.52% | ↗ |
| 83 | 2016 | Omead Ostadan Senior Vice President, Marketing, Products & Strategic Planning | 528.5K | — | 2.30M | — | — | 11.5K | 2.84M | 80.99% | ↗ |
| 84 | 2016 | Omead Ostadan Executive Vice President, Products and Operations | 528.5K | — | 2.30M | — | — | 11.5K | 2.84M | 80.99% | ↗ |
| 85 | 2016 | Omead Ostadan Executive Vice President, Operations, Products and Strategy | 528.5K | — | 2.30M | — | — | 11.5K | 2.84M | 80.99% | ↗ |
| 86 | 2016 | Charles E. Dadswell Senior Vice President, General Counsel & Secretary | 408.9K | — | 1.30M | — | — | 18.6K | 1.73M | 75.26% | ↗ |
| 87 | 2015 | Jay T. Flatley CEO; Chairman | 995.7K | — | 7.00M | — | 1.16M | 62.9K | 9.22M | 75.94% | ↗ |
| 88 | 2015 | Jay T. Flatley Executive Chairman | 995.7K | — | 7.00M | — | 1.16M | 62.9K | 9.22M | 75.94% | ↗ |
| 89 | 2015 | Francis A. deSouza President; Director | 748.5K | — | 4.00M | — | 556.2K | 97.1K | 5.40M | 74.05% | ↗ |
| 90 | 2015 | Francis A. deSouza President and CEO; Director | 748.5K | — | 4.00M | — | 556.2K | 97.1K | 5.40M | 74.05% | ↗ |
| 91 | 2015 | Marc A. Stapley Executive Vice President, Chief Administrative Officer | 501.0K | — | 2.30M | — | 401.3K | 11.1K | 3.21M | 71.58% | ↗ |
| 92 | 2015 | Marc A. Stapley Executive Vice President, Strategy and Corporate Development | 501.0K | — | 2.30M | — | 401.3K | 11.1K | 3.21M | 71.58% | ↗ |
| 93 | 2015 | Marc A. Stapley Executive Vice President, Chief Administrative Officer & CFO | 501.0K | — | 2.30M | — | 401.3K | 11.1K | 3.21M | 71.58% | ↗ |
| 94 | 2015 | Christian O. Henry Executive Vice President & Chief Commercial Officer | 499.5K | — | 2.30M | — | 301.3K | 66.9K | 3.17M | 72.61% | ↗ |
| 95 | 2015 | Tristan B. Orpin Executive Vice President, Clinical Genomics | 460.4K | — | 2.30M | — | 235.0K | 61.0K | 3.06M | 75.25% | ↗ |
| 96 | 2014 | Jay T. Flatley CEO; Chairman | 859.2K | — | 12.73M | — | 1.20M | 59.7K | 14.86M | 85.71% | ↗ |
| 97 | 2014 | Jay T. Flatley Executive Chairman | 859.2K | — | 12.73M | — | 1.20M | 59.7K | 14.86M | 85.71% | ↗ |
| 98 | 2014 | Jay T. Flatley Chief Executive Officer; Director | 859.2K | — | 12.73M | — | 1.20M | 59.7K | 14.86M | 85.71% | ↗ |
| 99 | 2014 | Francis A. deSouza President; Director | 689.2K | — | 4.80M | — | 784.0K | 100.1K | 6.37M | 75.31% | ↗ |
| 100 | 2014 | Francis A. deSouza President; Director | 689.2K | — | 4.80M | — | 784.0K | 100.1K | 6.37M | 75.31% | ↗ |
| 101 | 2014 | Francis A. deSouza President and CEO; Director | 689.2K | — | 4.80M | — | 784.0K | 100.1K | 6.37M | 75.31% | ↗ |
| 102 | 2014 | Marc A. Stapley Executive Vice President, Chief Administrative Officer & CFO | 463.3K | — | 3.30M | — | 357.1K | 16.3K | 4.14M | 79.78% | ↗ |
| 103 | 2014 | Marc A. Stapley Executive Vice President, Chief Administrative Officer | 463.3K | — | 3.30M | — | 357.1K | 16.3K | 4.14M | 79.78% | ↗ |
| 104 | 2014 | Marc A. Stapley Senior Vice President Chief Financial Officer | 463.3K | — | 3.30M | — | 357.1K | 16.3K | 4.14M | 79.78% | ↗ |
| 105 | 2014 | Christian O. Henry Senior Vice President Chief Commercial Officer | 467.5K | — | 3.03M | — | 365.8K | 62.8K | 3.92M | 77.15% | ↗ |
| 106 | 2014 | Christian O. Henry Executive Vice President & Chief Commercial Officer | 467.5K | — | 3.03M | — | 365.8K | 62.8K | 3.92M | 77.15% | ↗ |
| 107 | 2014 | Richard Klausner, M.D. | 403.7K | — | 2.88M | — | 315.7K | 76.2K | 3.67M | 78.33% | ↗ |
| 108 | 2013 | Jay T. Flatley CEO, Director | 829.4K | 250.0K | 5.21M | — | 986.9K | 17.9K | 7.30M | 71.44% | ↗ |
| 109 | 2013 | Jay T. Flatley CEO; Chairman | 829.4K | 250.0K | 5.21M | — | 986.9K | 17.9K | 7.30M | 71.44% | ↗ |
| 110 | 2013 | Jay T. Flatley Chief Executive Officer; Director | 829.4K | 250.0K | 5.21M | — | 986.9K | 17.9K | 7.30M | 71.44% | ↗ |
| 111 | 2013 | Francis A. deSouza President; Director | 13.5K | 140.0K | 6.57M | — | — | 240.00 | 6.73M | 97.72% | ↗ |
| 112 | 2013 | Francis A. deSouza President; Director | 13.5K | 140.0K | 6.57M | — | — | 240.00 | 6.73M | 97.72% | ↗ |
| 113 | 2013 | Charles E. Dadswell | 235.6K | — | 2.27M | — | 153.1K | 44.6K | 2.71M | 83.99% | ↗ |
| 114 | 2013 | Christian O. Henry Executive Vice President & Chief Commercial Officer | 457.1K | — | 1.47M | — | 295.1K | 19.6K | 2.24M | 65.61% | ↗ |
| 115 | 2013 | Christian O. Henry Senior Vice President Chief Commercial Officer | 457.1K | — | 1.47M | — | 295.1K | 19.6K | 2.24M | 65.61% | ↗ |
| 116 | 2013 | Marc A. Stapley Senior Vice President CFO | 447.7K | — | 1.47M | — | 288.1K | 12.5K | 2.22M | 66.31% | ↗ |
| 117 | 2013 | Marc A. Stapley Executive Vice President, Chief Administrative Officer & CFO | 447.7K | — | 1.47M | — | 288.1K | 12.5K | 2.22M | 66.31% | ↗ |
| 118 | 2013 | Marc A. Stapley Senior Vice President Chief Financial Officer | 447.7K | — | 1.47M | — | 288.1K | 12.5K | 2.22M | 66.31% | ↗ |
| 119 | 2012 | Jay T. Flatley CEO, Director | 803.0K | 200.0K | 6.29M | — | 862.9K | 17.0K | 8.17M | 76.96% | ↗ |
| 120 | 2012 | Jay T. Flatley Chief Executive Officer; Director | 803.0K | 200.0K | 6.29M | — | 862.9K | 17.0K | 8.17M | 76.96% | ↗ |
| 121 | 2012 | Jay T. Flatley President, Chief Executive Officer Director | 803.0K | 200.0K | 6.29M | — | 862.9K | 17.0K | 8.17M | 76.96% | ↗ |
| 122 | 2012 | Marc A. Stapley Senior Vice President CFO | 403.2K | 350.0K | 889.4K | 1.84M | 239.6K | 232.1K | 3.95M | 69.00% | ↗ |
| 123 | 2012 | Marc A. Stapley Senior Vice President Chief Financial Officer | 403.2K | 350.0K | 889.4K | — | 239.6K | 232.1K | 3.95M | 22.51% | ↗ |
| 124 | 2012 | Marc A. Stapley Senior Vice President Chief Financial Officer | 403.2K | 350.0K | 889.4K | 1.84M | 239.6K | 232.1K | 3.95M | 69.00% | ↗ |
| 125 | 2012 | Nicholas J Naclerio Senior Vice President, Corporate Venture Development | 399.6K | 50.0K | 3.09M | — | 230.2K | 8.6K | 3.78M | 81.78% | ↗ |
| 126 | 2012 | Matthew L. Posard Senior Vice President General Manager, Translational Consumer Genomics | 379.4K | — | 2.28M | — | 217.0K | 10.5K | 2.89M | 78.97% | ↗ |
| 127 | 2012 | Christian O. Henry Senior Vice President, General Manager, Genomic Systems | 449.7K | — | 1.98M | — | 258.4K | 24.5K | 2.71M | 72.95% | ↗ |
| 128 | 2012 | Christian O. Henry Senior Vice President Chief Commercial Officer | 449.7K | — | 1.98M | — | 258.4K | 24.5K | 2.71M | 72.95% | ↗ |
| 129 | 2012 | Paul L. Bianchi Senior Vice President, Human Resources | 105.0K | — | 2.42M | — | 64.9K | 644.00 | 2.59M | 93.41% | ↗ |
| 130 | 2011 | Jay T. Flatley President, Chief Executive Officer Director | 779.4K | — | 1.77M | — | 651.0K | 16.4K | 9.94M | 17.80% | ↗ |
| 131 | 2011 | Jay T. Flatley CEO, Director | 779.4K | — | 1.77M | — | 651.0K | 16.4K | 9.94M | 17.80% | ↗ |
| 132 | 2011 | Christian O. Henry Senior Vice President Chief Commercial Officer | 429.8K | — | 416.0K | 2.40M | 197.5K | 17.5K | 3.46M | 81.37% | ↗ |
| 133 | 2011 | Christian O. Henry Senior Vice President, General Manager, Genomic Systems | 429.8K | — | 416.0K | — | 197.5K | 17.5K | 3.46M | 12.02% | ↗ |
| 134 | 2011 | Nicholas J Naclerio Senior Vice President, Corporate Venture Development | 339.3K | — | 433.4K | — | 159.6K | 10.5K | 2.59M | 16.74% | ↗ |
| 135 | 2011 | Matthew L. Posard Senior Vice President General Manager, Translational Consumer Genomics | — | — | — | — | — | — | — | — | ↗ |
| 136 | 2010 | Jay T. Flatley President, Chief Executive Officer Director | 749.6K | — | 907.5K | — | 922.5K | 22.3K | 6.61M | 13.73% | ↗ |
| 137 | 2010 | Christian O. Henry Senior Vice President, Chief Financial Officer General | 410.1K | — | — | — | — | — | 2.21M | 0.00% | ↗ |
| 138 | 2010 | Christian O. Henry Senior Vice President, General Manager, Genomic Systems | 410.1K | — | 277.8K | — | 277.5K | 15.7K | 2.21M | 12.58% | ↗ |
| 139 | 2010 | Tristan B. Orpin Senior Vice President Chief Commercial Officer | 379.4K | — | — | — | — | — | 2.16M | 0.00% | ↗ |
| 140 | 2010 | Christian G. Cabou Senior Vice President, General Counsel Secretary | 367.9K | — | — | — | — | — | 2.14M | 0.00% | ↗ |
| 141 | 2010 | Mostafa Ronaghi Senior Vice President Chief Technology Officer | 337.8K | — | — | — | — | — | 2.08M | 0.00% | ↗ |
| 142 | 2010 | Nicholas J Naclerio Senior Vice President, Corporate Venture Development | — | — | — | — | — | — | — | — | ↗ |
| 143 | 2010 | Matthew L. Posard Senior Vice President General Manager, Translational Consumer Genomics | — | — | — | — | — | — | — | — | ↗ |
| 144 | 2009 | Jay T. Flatley President, Chief Executive Officer Director | 749.2K | — | — | — | — | — | 5.70M | 0.00% | ↗ |
| 145 | 2009 | Christian O. Henry Senior Vice President, Chief Financial Officer General | 390.2K | — | — | — | — | — | 2.23M | 0.00% | ↗ |
| 146 | 2009 | Christian O. Henry Senior Vice President, Chief Financial Officer General Manager, Life Sciences | 390.2K | — | — | — | — | — | 2.23M | 0.00% | ↗ |
| 147 | 2009 | Tristan B. Orpin Senior Vice President Chief Commercial Officer | 380.1K | — | — | — | — | — | 1.88M | 0.00% | ↗ |
| 148 | 2009 | Tristan B. Orpin Senior Vice President, Commercial Operations | 380.1K | — | — | — | — | — | 1.88M | 0.00% | ↗ |
| 149 | 2009 | Christian G. Cabou Senior Vice President, General Counsel Secretary | 366.7K | — | — | — | — | — | 1.86M | 0.00% | ↗ |
| 150 | 2009 | Gregory F. Heath | 398.9K | — | — | — | — | — | 1.67M | 0.00% | ↗ |
| 151 | 2009 | Mostafa Ronaghi Senior Vice President Chief Technology Officer | — | — | — | — | — | — | — | — | ↗ |
| 152 | 2008 | Jay T. Flatley President, Chief Executive Officer Director | 647.0K | — | — | — | — | — | 6.22M | 0.00% | ↗ |
| 153 | 2008 | Jay T. Flatley President, Chief Executive Officer and Director | 647.0K | — | 114.6K | — | 604.5K | 27.8K | 5.12M | 2.24% | ↗ |
| 154 | 2008 | Christian O. Henry Senior Vice President, Chief Financial Officer General | 343.1K | — | — | — | — | — | 2.56M | 0.00% | ↗ |
| 155 | 2008 | Christian O. Henry Senior Vice President, Chief Financial Officer General Manager, Life Sciences | 343.1K | — | — | — | — | — | 2.56M | 0.00% | ↗ |
| 156 | 2008 | Tristan B. Orpin Senior Vice President Chief Commercial Officer | 351.2K | — | — | — | — | — | 2.32M | 0.00% | ↗ |
| 157 | 2008 | Tristan B. Orpin Senior Vice President, Commercial Operations | 351.2K | — | — | — | — | — | 2.32M | 0.00% | ↗ |
| 158 | 2008 | Christian G. Cabou Senior Vice President, General Counsel Secretary | 336.1K | — | — | — | — | — | 2.29M | 0.00% | ↗ |
| 159 | 2008 | Christian O. Henry Senior Vice President, Chief Financial Officer | 343.1K | — | 44.5K | — | 313.9K | 6.8K | 2.05M | 2.16% | ↗ |
| 160 | 2008 | Christian G. Cabou Senior Vice President, General Counsel and Secretary | 336.1K | — | 40.8K | — | 205.6K | 9.9K | 1.89M | 2.16% | ↗ |
| 161 | 2008 | Joel McComb Senior Vice President General Manager, Life Sciences | 356.3K | — | — | — | 237.5K | 120.0K | 1.82M | 0.00% | ↗ |
| 162 | 2008 | Mostafa Ronaghi Senior Vice President Chief Technology Officer | — | — | — | — | — | — | — | — | ↗ |
| 163 | 2007 | Jay T. Flatley President, Chief Executive Officer Director | 575.6K | — | — | — | — | — | 10.33M | 0.00% | ↗ |
| 164 | 2007 | John West Former Senior Vice President and General Manager, Sequencing | 360.6K | 4.22M | — | 1.18M | — | — | 5.77M | 20.51% | ↗ |
| 165 | 2007 | Christian O. Henry Senior Vice President, Chief Financial Officer General Manager, Life Sciences | 298.1K | — | — | — | — | — | 4.43M | 0.00% | ↗ |
| 166 | 2007 | Jay T. Flatley President, Chief Executive Officer and Director | 575.6K | — | — | — | 432.7K | 22.9K | 3.86M | 0.00% | ↗ |
| 167 | 2007 | Tristan B. Orpin Senior Vice President, Commercial Operations | 321.0K | — | — | — | — | — | 3.20M | 0.00% | ↗ |
| 168 | 2007 | Christian G. Cabou Senior Vice President, General Counsel Secretary | 314.0K | — | — | — | — | — | 2.46M | 0.00% | ↗ |
| 169 | 2007 | John R. Stuelpnagel Co-Founder, Former Senior Vice President, General Manager, Microarrays, Chief Operating Officer and Director | 348.8K | 124.8K | — | 1.39M | — | 15.0K | 1.88M | 74.05% | ↗ |
| 170 | 2007 | Christian O. Henry Senior Vice President, Chief Financial Officer | 298.1K | — | — | — | 144.5K | 6.8K | 1.44M | 0.00% | ↗ |
| 171 | 2007 | Christian G. Cabou Senior Vice President, General Counsel and Secretary | 314.0K | — | — | — | 154.3K | 4.0K | 1.41M | 0.00% | ↗ |
| 172 | 2007 | Christian O. Henry Senior Vice President, Chief Financial Officer and Acting General Manager, Sequencing | 298.1K | 97.5K | — | 986.1K | — | — | 1.38M | 71.37% | ↗ |
| 173 | 2007 | Arthur L. Holden Former Senior Vice President, Corporate and Market Development | 252.1K | 83.4K | — | 619.4K | — | 1.7K | 956.5K | 64.75% | ↗ |
| 174 | 2007 | Joel McComb Senior Vice President General Manager, Life Sciences | — | — | — | — | — | — | — | — | ↗ |
| 175 | 2006 | Jay T. Flatley President, Chief Executive Officer and Director | 463.5K | — | — | — | 302.3K | 2.4K | 2.05M | 0.00% | ↗ |
| 176 | 2006 | Jay T. Flatley President, Chief Executive Officer and Director | 463.5K | 149.2K | — | 1.18M | — | — | 1.80M | 65.73% | ↗ |
| 177 | 2006 | John R. Stuelpnagel Co-Founder, Former Senior Vice President, General Manager, Microarrays, Chief Operating Officer and Director | 319.2K | 58.5K | — | 631.6K | — | — | 1.02M | 61.87% | ↗ |
| 178 | 2006 | John R. Stuelpnagel Co-Founder, Former Senior Vice President, General Manager, Microarrays, Chief Operating Officer and Director | 319.2K | 58.5K | — | 631.6K | — | 7.8K | 1.02M | 62.09% | ↗ |
| 179 | 2006 | Tristan B. Orpin Senior Vice President, Commercial Operations | 219.2K | — | — | — | 72.5K | 171.1K | 738.4K | 0.00% | ↗ |
| 180 | 2006 | Christian O. Henry Senior Vice President, Chief Financial Officer | 249.6K | — | — | — | 97.5K | 1.8K | 737.8K | 0.00% | ↗ |
| 181 | 2006 | Tristan B. Orpin Senior Vice President, Commercial Operations | 219.2K | 25.2K | — | 272.1K | — | — | 689.1K | 39.48% | ↗ |
| 182 | 2006 | Christian O. Henry Senior Vice President, Chief Financial Officer and Acting General Manager, Sequencing | 249.6K | 27.3K | — | 378.6K | — | — | 658.9K | 57.46% | ↗ |
| 183 | 2006 | Christian O. Henry Senior Vice President, Chief Financial Officer and Acting General Manager, Sequencing | 249.6K | 27.3K | — | 378.6K | — | — | 655.5K | 57.76% | ↗ |
| 184 | 2006 | Christian G. Cabou Senior Vice President, General Counsel and Secretary | 161.7K | — | — | — | 65.9K | 40.0K | 602.0K | 0.00% | ↗ |
| 185 | 2006 | Arthur L. Holden Former Senior Vice President, Corporate and Market Development | 202.8K | — | — | 322.1K | — | — | 529.2K | 60.87% | ↗ |
| 186 | 2006 | Arthur L. Holden Former Senior Vice President, Corporate and Market Development | 202.8K | — | — | 322.1K | — | — | 524.9K | 61.36% | ↗ |
| 187 | 2006 | Christian G. Cabou Senior Vice President, General Counsel and Secretary | 161.7K | — | — | 292.3K | — | — | 494.0K | 59.16% | ↗ |
| 188 | 2006 | Joel McComb Senior Vice President General Manager, Life Sciences | — | — | — | — | — | — | — | — | ↗ |
| 189 | 2006 | John West Former Senior Vice President and General Manager, Sequencing | — | — | — | — | — | — | — | — | ↗ |
| 190 | 2005 | Jay T. Flatley, President and Chief Executive Officer | 424.3K | 149.2K | — | — | — | — | 573.5K | 0.00% | ↗ |
| 191 | 2005 | John R. Stuelpnagel, Senior Vice President and Chief Operating Officer | 299.4K | 58.5K | — | — | — | 7.9K | 365.8K | 0.00% | ↗ |
| 192 | 2005 | Tristan B. Orpin, Vice President of Worldwide Sales | 197.7K | 25.2K | — | — | — | 116.9K | 339.8K | 0.00% | ↗ |
| 193 | 2005 | David L. Barker, Ph.D Vice President and Chief Scientific Officer | 242.2K | 35.3K | — | — | — | — | 277.5K | 0.00% | ↗ |
| 194 | 2005 | Christian O. Henry, Vice President and Chief Financial Officer | 129.2K | 27.3K | — | — | — | — | 156.5K | 0.00% | ↗ |
| 195 | 2004 | Jay T. Flatley, President and Chief Executive Officer | 399.3K | 147.7K | — | — | — | — | 547.1K | 0.00% | ↗ |
| 196 | 2004 | John R. Stuelpnagel, Senior Vice President and Chief Operating Officer | 275.0K | 46.8K | — | — | — | 7.4K | 329.2K | 0.00% | ↗ |
| 197 | 2004 | John R. Stuelpnagel, Senior Vice President and Chief Operating Officer | 275.0K | 46.8K | — | — | — | — | 321.8K | 0.00% | ↗ |
| 198 | 2004 | Timothy M. Kish, | 267.5K | 48.2K | — | — | — | — | 315.7K | 0.00% | ↗ |
| 199 | 2004 | Tristan B. Orpin, Vice President of Worldwide Sales | 179.2K | 18.0K | — | — | — | 118.4K | 315.6K | 0.00% | ↗ |
| 200 | 2004 | David L. Barker, Ph.D Vice President and Chief Scientific Officer | 233.2K | 28.0K | — | — | — | — | 261.2K | 0.00% | ↗ |
| 201 | 2004 | Noemi C. Espinosa Vice President of Intellectual Property | 231.0K | 20.8K | — | — | — | — | 251.8K | 0.00% | ↗ |
| 202 | 2004 | Christian O. Henry, Vice President and Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
| 203 | 2003 | Jay T. Flatley President and Chief Executive Officer | 360.4K | 96.1K | — | — | — | 22.5K | 479.0K | 0.00% | ↗ |
| 204 | 2003 | Jay T. Flatley, President and Chief Executive Officer | 360.4K | 96.1K | — | — | — | 22.5K | 479.0K | 0.00% | ↗ |
| 205 | 2003 | John R. Stuelpnagel, Senior Vice President and Chief Operating Officer | 250.0K | 33.3K | — | — | — | 7.2K | 290.6K | 0.00% | ↗ |
| 206 | 2003 | John R. Stuelpnagel Senior Vice President of Operations | 250.0K | 33.3K | — | — | — | 7.2K | 290.6K | 0.00% | ↗ |
| 207 | 2003 | Timothy M. Kish Vice President of Finance and Chief Financial Officer | 250.0K | 33.3K | — | — | — | — | 283.3K | 0.00% | ↗ |
| 208 | 2003 | David L. Barker Vice President and Chief Scientific Officer | 220.0K | 22.0K | — | — | — | — | 242.0K | 0.00% | ↗ |
| 209 | 2003 | David L. Barker, Ph.D Vice President and Chief Scientific Officer | 220.0K | 22.0K | — | — | — | — | 242.0K | 0.00% | ↗ |
| 210 | 2003 | Noemi C. Espinosa Vice President of Intellectual Property | 220.0K | 14.7K | — | — | — | 4.2K | 238.8K | 0.00% | ↗ |
| 211 | 2003 | Tristan B. Orpin, Vice President of Worldwide Sales | 155.0K | 25.3K | — | — | — | 47.2K | 227.6K | 0.00% | ↗ |
| 212 | 2003 | Christian O. Henry, Vice President and Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
| 213 | 2002 | Jay T. Flatley President and Chief Executive Officer | 340.0K | 119.0K | — | — | — | 7.5K | 466.5K | 0.00% | ↗ |
| 214 | 2002 | Timothy M. Kish Vice President of Finance and Chief Financial Officer | 236.3K | 17.7K | — | — | — | — | 254.0K | 0.00% | ↗ |
| 215 | 2002 | John R. Stuelpnagel Senior Vice President of Operations | 220.0K | 22.0K | — | — | — | 3.9K | 245.9K | 0.00% | ↗ |
| 216 | 2002 | Noemi C. Espinosa Vice President of Intellectual Property | 210.0K | 12.6K | — | — | — | 4.0K | 226.6K | 0.00% | ↗ |
| 217 | 2002 | David L. Barker Vice President and Chief Scientific Officer | 210.0K | 15.8K | — | — | — | — | 225.8K | 0.00% | ↗ |
| 218 | 2001 | Jay T. Flatley President and Chief Executive Officer | 299.5K | 82.5K | — | — | — | — | 382.0K | 0.00% | ↗ |
| 219 | 2001 | Timothy M. Kish Vice President of Finance and Chief Financial Officer | 225.0K | 11.3K | — | — | — | — | 236.3K | 0.00% | ↗ |
| 220 | 2001 | Noemi C. Espinosa Vice President of Intellectual Property | 200.0K | 10.0K | — | — | — | — | 210.0K | 0.00% | ↗ |
| 221 | 2001 | David L. Barker Vice President and Chief Scientific Officer | 200.0K | 10.0K | — | — | — | — | 210.0K | 0.00% | ↗ |
| 222 | 2001 | John R. Stuelpnagel Senior Vice President of Operations | 189.7K | 9.5K | — | — | — | 7.7K | 206.9K | 0.00% | ↗ |
| 223 | 2001 | John R. Stuelpnagel Vice President of Business Development | 189.7K | 9.5K | — | — | — | 7.7K | 206.9K | 0.00% | ↗ |
| 224 | 2000 | Jay T. Flatley President and Chief Executive Officer | 269.7K | 82.5K | — | — | — | 56.3K | 408.5K | 0.00% | ↗ |
| 225 | 2000 | Jay T. Flatley President and Chief Executive Officer | 269.7K | 82.5K | — | — | — | — | 352.2K | 0.00% | ↗ |
| 226 | 2000 | Timothy M. Kish Vice President of Finance and Chief Financial Officer | 146.3K | — | — | — | — | 50.0K | 196.3K | 0.00% | ↗ |
| 227 | 2000 | David L. Barker Vice President and Chief Scientific Officer | 155.4K | — | — | — | — | 20.0K | 175.4K | 0.00% | ↗ |
| 228 | 2000 | John R. Stuelpnagel Vice President of Business Development | 174.4K | — | — | — | — | — | 174.4K | 0.00% | ↗ |
| 229 | 2000 | John R. Stuelpnagel Senior Vice President of Operations | 174.4K | — | — | — | — | — | 174.4K | 0.00% | ↗ |
| 230 | 2000 | John R. Stuelpnagel Vice President of Business Development | 174.4K | — | — | — | — | — | 174.4K | 0.00% | ↗ |
| 231 | 2000 | Mark S. Chee | 171.0K | — | — | — | — | — | 171.0K | 0.00% | ↗ |
| 232 | 2000 | David L. Barker Vice President and Chief Scientific Officer | 155.4K | — | — | — | — | — | 155.4K | 0.00% | ↗ |
| 233 | 2000 | Noemi C. Espinosa Vice President of Intellectual Property | 130.8K | — | — | — | — | 20.0K | 150.8K | 0.00% | ↗ |
| 234 | 2000 | Timothy M. Kish Vice President of Finance and Chief Financial Officer | 146.3K | — | — | — | — | — | 146.3K | 0.00% | ↗ |
| 235 | 1999 | John R. Stuelpnagel Vice President of Business Development | 141.5K | 12.0K | — | — | — | — | 153.5K | 0.00% | ↗ |
| 236 | 1999 | Jay T. Flatley President and Chief Executive Officer | 55.9K | — | — | — | — | 11.7K | 67.6K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jacob Thaysen | CEO, Interim Chief Commercial Officer & Director | 2M | male |
| Ankur Dhingra | Chief Financial Officer | 986.0K | male |
| Steven Barnard | Chief Technology Officer | 918.0K | — |
| Kevin Carl Pegels | Chief of Global Operations | 883.0K | male |
| Mark Field | Chief Information Officer | 693.5K | male |
| Scott Davies | Chief Legal Officer & Secretary | — | male |
| Scott Ericksen | Vice President & Chief Accounting Officer | — | male |
| Stephanie Campos | President | — | — |
| Jakob Wedel | Chief Strategy & Corporate Development Officer | — | male |
| Conor Noel McNamara | Vice President of Investor Relations | — | male |
| Patricia Leckman | Senior Vice President & Chief People Officer | — | female |
ESG Rating
ESG Score History MEDICAL - DIAGNOSTICS & RESEARCH
Benchmark vs Sector
Political Trading Activity (25M)
Senate Trading Activity
House Trading Activity
| Transaction Date | Disclosed | Representative | District | Owner | Type | Amount | Link |
|---|---|---|---|---|---|---|---|
| 2026-02-10 | 2026-03-10 | Gilbert Cisneros | CA31 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2025-06-09 | 2025-08-13 | Lisa McClain | MI09 | Spouse | Purchase | $1,001 - $15,000 | ↗ |
| 2025-04-01 | 2025-05-15 | Thomas H. Kean | NJ07 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2025-04-01 | 2025-04-21 | Thomas H. Kean | NJ07 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2024-09-03 | 2024-09-24 | Michael C. Burgess | TX26 | Spouse | Sale (Full) | $15,001 - $50,000 | ↗ |
| 2024-08-30 | 2024-10-01 | Michael C. Burgess | TX26 | — | Sale (Full) | $15,001 - $50,000 | ↗ |
| 2024-04-19 | 2024-05-30 | Thomas H. Kean | NJ07 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2024-03-11 | 2024-03-22 | Michael C. Burgess | TX26 | — | Sale (Partial) | $1,001 - $15,000 | ↗ |
| 2024-02-12 | 2024-03-07 | Michael C. Burgess | TX26 | Self | Sale (Partial) | $1,001 - $15,000 | ↗ |
| 2024-02-12 | 2024-03-07 | Michael C. Burgess | TX26 | Self | Purchase | $15,001 - $50,000 | ↗ |
| 2024-02-09 | 2024-03-07 | Michael C. Burgess | TX26 | Self | Sale (Partial) | $1,001 - $15,000 | ↗ |
| 2024-01-02 | 2024-01-22 | Michael C. Burgess | TX26 | Spouse | Sale (Partial) | $1,001 - $15,000 | ↗ |
| 2024-01-02 | 2024-01-22 | Michael C. Burgess | TX26 | Spouse | Purchase | $15,001 - $50,000 | ↗ |
| 2024-01-02 | 2024-01-22 | Michael C. Burgess | TX26 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2023-11-03 | 2023-12-06 | Ro Khanna | CA17 | — | Sale | $1,001 - $15,000 | ↗ |
| 2023-10-31 | 2023-11-08 | Ro Khanna | CA17 | Spouse | Purchase | $1,001 - $15,000 | ↗ |
| 2023-10-02 | 2023-11-08 | Ro Khanna | CA17 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2023-08-29 | 2023-09-06 | Ro Khanna | CA17 | — | Sale | $1,001 - $15,000 | ↗ |
| 2023-07-28 | 2023-08-07 | Ro Khanna | CA17 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2023-06-29 | 2023-07-11 | Ro Khanna | CA17 | Spouse | Sale | $1,001 - $15,000 | ↗ |
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ILMN
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
